NCT00940602 - Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study | Biotech Hunter

Enrollment

225

Participants

Timeline

Start Date

March 22, 2010

Primary Completion Date

February 27, 2018

Study Completion Date

February 27, 2018

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

Deferasirox

Deferasirox provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use

DRUG

Placebo

Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use

Trial Locations (71)

1309

Novartis Investigative Site, Auckland

1407

Novartis Investigative Site, Sofia

4002

Novartis Investigative Site, Plovdiv

4029

Novartis Investigative Site, Herston

4031

Novartis Investigative Site, Basel

8001

Novartis Investigative Site, Christchurch

8091

Novartis Investigative Site, Zurich

9010

Novartis Investigative Site, Varna

10043

Novartis Investigative Site, Orbassano

10330

Novartis Investigative Site, Bangkok

10400

Novartis Investigative Site, Bangkok

40002

Novartis Investigative Site, Khon Kaen

40138

Novartis Investigative Site, Bologna

48202

Henry Ford Hospital Henry Ford, Detroit

50134

Novartis Investigative Site, Florence

50200

Novartis Investigative Site, Chiang Mai

51000

Novartis Investigative Site, Guangzhou

59901

Glacier View Research Institute - Cancer SC, Kalispell

63021

Mercy Medical Research Institute SC, Manchester

64131

Midwest Cancer Care Physicians MMCC, Kansas City

65124

Novartis Investigative Site, Pescara

68000

Novartis Investigative Site, Kuala Selangor

71013

Novartis Investigative Site, San Giovanni Rotondo

71103

Willis-Knighton Cancer Center Dept of Onc, Shreveport

77030

University of Texas MD Anderson Cancer Center Dept of MD Anderson (16), Houston

78229

Cancer Care Centers of South Texas HOAST CCC of So.TX- MedicalCenter(2), San Antonio

89124

Novartis Investigative Site, Reggio Calabria

92801

Pacific Cancer Medical Center, Inc. PAC Center, Anaheim

93586

Novartis Investigative Site, Kuching

98107

Swedish Cancer Institute Ballard Campus, Seattle

98125

Novartis Investigative Site, Messina

100044

Novartis Investigative Site, Beijing

125167

Novartis Investigative Site, Moscow

200025

Novartis Investigative Site, Shanghai

200233

Novartis Investigative Site, Shanghai

200437

Novartis Investigative Site, Shanghai

210029

Novartis Investigative Site, Nanjing

215006

Novartis Investigative Site, Suzhou

250012

Novartis Investigative Site, Jinan

300020

Novartis Investigative Site, Tianjin

310003

Novartis Investigative Site, Hangzhou

344022

Novartis Investigative Site, Rostov-on-Don

430022

Novartis Investigative Site, Wuhan

Unknown

Rocky Mountain Cancer Centers RMCC, Greenwood Village

Novartis Investigative Site, Shatin, New Territories

Novartis Investigative Site, Hong Kong

Novartis Investigative Site, Auckland

07601

Hackensack University Medical Center Department of Research, Hackensack

T6G 2B7

Novartis Investigative Site, Edmonton

R3E 0V9

Novartis Investigative Site, Winnipeg

L6R 3J7

Novartis Investigative Site, Brampton

L2S 0A9

Novartis Investigative Site, St. Catharines

G1J 1Z4

Novartis Investigative Site, Québec

DK-2100

Novartis Investigative Site, Copenhagen

DK 2730

Novartis Investigative Site, Herlev

115 27

Novartis Investigative Site, Athens

455 00

Novartis Investigative Site, Ioannina

265 00

Novartis Investigative Site, Pátrai

09126

Novartis Investigative Site, Cagliari

02990

Novartis Investigative Site, Mexico City

06726

Novartis Investigative Site, Mexico City

G12 0YN

Novartis Investigative Site, Glasgow

B15 2TH

Novartis Investigative Site, Birmingham

BH7 7DW

Novartis Investigative Site, Bournemouth

CF14 4XW

Novartis Investigative Site, Cardiff

EX2 5DW

Novartis Investigative Site, Exeter

DA2 8DA

Novartis Investigative Site, Kent

SK10 3BL

Novartis Investigative Site, Macclesfield

NG5 1PB

Novartis Investigative Site, Nottingham

OX3 7LJ

Novartis Investigative Site, Oxford